Torrent Pharma Q1FY24 Results: Consolidated PAT Rises to Rs. 378 Cr

Torrent Pharma Q1FY24 Results: Consolidated PAT Rises to Rs. 378 Cr

Torrent Pharma Q1 results show revenue up from 2500 crores to 2625 crores, a 5%% increase in growth. EPS rise from ₹8.48 to ₹11.18, up by 31.84%.

First, Let’s Begin with Quarter-on-Quarter Basis:

Torrent Pharma shared its Q1 results on Monday. They earned 2625 crores in revenue this quarter, but that’s more than the 2500 crores they made last quarter. The company’s growth increased by 5% percent when comparing the two quarters.

In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 378 crores, up from 287 crores in the previous quarter. Their quarter-to-quarter growth increased by 31.71 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹11.18, which is an increase of 31.84% from the ₹8.48 EPS in the previous quarter.

Now, Let’s Analyze the Results on a Year-over-Year Basis:

The company made a total revenue of 2625 crores this year (2023), which is 10.43 percent higher than last year’s total revenue of 2377 crores.

This year’s PAT (Profit After Tax) is 378 crores, which is also 6.78% higher than last year’s PAT of 354 crores.

The EPS (Earnings Per Share) for this year is ₹11.18, which is 6.99% more than the EPS of ₹10.45 earned last year.

Also Read: Godrej Consumer Q1FY24 Results: Consolidated PAT of Rs. 318.82 Cr

Torrent Pharma Share Dividend Announcement / Record Date:

The record date for the dividend has not arrived yet.

About Torrent Pharma:

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, with its ownership under the Torrent Group and its headquarters situated in Ahmedabad. Originally known as Trinity Laboratories Ltd and promoted by U. N. Mehta, the company underwent a name change and became Torrent Pharmaceuticals Ltd at a later stage.

Download the Full PDF of Torrent Pharma Q1 Results: Click Here

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *